Life Sciences

Overview


Chambers USA 2018, Client Quote

Whether you’re a cutting-edge medical device startup or a global biopharma leader, it’s mission that drives you. Amid pricing and payor pressures, regulatory scrutiny, emerging innovations and challenging pipelines, market demand continues to grow. To broaden your field of vision as you navigate this dynamic industry, you need integrated, global counsel that can help clear your path to success.

McDermott’s Life Sciences Team will get you closer to your goals. Composed of top lawyers with demonstrated strength across intellectual property, regulatory, transactional and litigation law, we’re a purpose-built team of thought leaders united by a passion for our work. Our team can meet the legal needs of life sciences companies at every stage of development. For decades, we have embraced the value of focused knowledge, harnessing both the particular skills of individuals and the collective experience of our team. This makes us uniquely qualified to help you move business initiatives across the finish line when it matters and anticipate what’s next.

Show More

Results


  • McDermott represented EPiX Therapeutics, Inc., a privately-held medical device company, in its sale to Medtronic plc (NYSE: MDT), one of the world’s largest medical device companies.
  • The McDermott team secured a jury verdict win for Firm client Amgen (NYSE: AMGN) in its long-fought battle with Sanofi and Regeneron Pharmaceuticals. The Delaware jury upheld the validity of two Amgen patents that cover PCSK9 antibody therapeutics, which help reduce low-density lipoproteins (LDL) or “bad” cholesterol. This is the team’s second win in the case, following remand after the first jury trial win in 2016 and an appeal to the Federal Circuit Court of Appeals.
  • McDermott represented Innate Pharma on a $1.2 billion partnering agreement with AstraZeneca (NYSE: AZN)
  • McDermott developed market pathway and FDA engagement strategies for a clinical laboratory for laboratory developed tests (LDTs), companion diagnostics and other products under FDA’s evolving regulatory paradigm for personalized medicine
  • McDermott advised Ampersand Capital Partners in its cross-border investment in Canopy Biosciences and simultaneous acquisition of Zellkraftwerk
  • McDermott represented one of China’s leading pharmaceutical company in a series of its investment and acquisition projects, including its outbound investment in the Middle East, complex milestone investments and biotech start-ups. The projects have involved several orphan drugs in the pipeline.
  • McDermott counseled Baxter (NYSE: BAX) on its acquisition of a portfolio of two hemostasis product lines for approximately $185 million from Mallinckrodt plc (NYSE: MNK), with an upfront payment of $153 million and the remainder in potential future milestones

Show More

People


McDermott’s Life Sciences Team will get you closer to your goals. Composed of top lawyers with demonstrated strength across intellectual property, regulatory, transactional and litigation law, we’re a purpose-built team of thought leaders united by a passion for our work.

Life Sciences

Insights & Events / Media

Cambridge, MA / McDermott Event / October 16, 2019

Cambridge, MA / McDermott Event / October 15-16, 2019

San Francisco, California / Speaking Engagements / September 26, 2019

Boston, Massachusetts / Speaking Engagements / September 24, 2019

Boston, Massachusetts / Speaking Engagements / September 22, 2019

International News / September 2019

Lincolnshire, IL / McDermott Event / May 14, 2019

Washington, DC / Speaking Engagements / April 30, 2019

Boston, MA / Speaking Engagements / April 25, 2019

On the Subject / December 10, 2018

Shanghai, China / McDermott Event / December 5, 2018

Webinar / McDermott Event / November 19, 2018

Pharm. Ind. 80, Issue 10 / November 2018

New York, New York / Speaking Engagements / November 5, 2018

IP Update / October 2018

Boston, Massachusetts / Speaking Engagements / October 17, 2018

Boston, Massachusetts / McDermott Event / October 10, 2018

Cambridge, Massachusetts / McDermott Event / October 9, 2018

Utica, New York / Speaking Engagements / September 27, 2018

Paris, France / McDermott Event / September 25, 2018

Cambridge, Massachusetts / McDermott Event / September 12, 2018

Boston, Massachusetts / Speaking Engagements / August 20, 2018

/ July 2018

Paris, France / McDermott Event / July 10, 2018

Paris, France / McDermott Event / June 28, 2018

On the Subject / June 15, 2018

Copenhagen, Denmark / McDermott Event / June 13, 2018

Copenhagen, Denmark / Speaking Engagements / June 12, 2018

Copenhagen, Denmark / Speaking Engagements / June 12, 2018

Copenhagen, Denmark / Speaking Engagements / June 11, 2018

Boston, Massachusetts / Speaking Engagements / June 5, 2018

Boston, Massachusetts / Speaking Engagements / June 4-7, 2018

Boston, Massachusetts / Speaking Engagements / June 4, 2018

Boston, Massachusetts / Speaking Engagements / June 3, 2018

Boston, Massachusetts / Speaking Engagements / June 1, 2018

Boston, Massachusetts / Speaking Engagements / May 31, 2018

Princeton, New Jersey / Speaking Engagements / May 6, 2018

Boston, Massachusetts / Speaking Engagements / May 3, 2018

Waltham, Massachusetts / Speaking Engagements / May 3, 2018

Washington, District of Columbia / Speaking Engagements / May 3-4, 2018

Boston, Massachusetts / Speaking Engagements / May 3, 2018

Boston, Massachusetts / Speaking Engagements / April 26, 2018

Special Report / April 25, 2018

Washington, District of Columbia / Speaking Engagements / April 23-25, 2018

Paris, France / Speaking Engagements / April 4, 2018

Scottsdale, Arizona / Speaking Engagements / March 25–28, 2018

China / / March 2018

AHLA (American Health Lawyers Association) / March 2018

Stanford, California / Speaking Engagements / February 14, 2018

San Francisco, California / Speaking Engagements / January 9, 2018

San Francisco, California / McDermott Event / January 9, 2018

San Francisco, California / McDermott Event / January 8, 2018

San Francisco, California / McDermott Event / January 8, 2018

IP Update / December 2017

Cambridge, Massachusetts / Speaking Engagements / December 11, 2017

IP Update / November 2017

GesR, Issue 11 / November 2017

Patient Individual Blister of Medicines in the Care of the Elderly

Shanghai, China / McDermott Event / November 16, 2017

/ November 2017

New York, New York / Speaking Engagements / October 5, 2017

Cambridge, Massachusetts / Speaking Engagements / October 4, 2017

Cambridge, Massachusetts / McDermott Event / October 4, 2017

Life Sciences Symposium / October 4, 2017

On the Subject / September 29, 2017

Munich, Germany / McDermott Event / September 19, 2017

International News / September 2017

IP Update / August 2017

New York, New York / Speaking Engagements / July 13, 2017

PharmaR, Issue 4 / April 30, 2017

Re-Introduction of the Prohibition of Online Sales of Rx-Drugs – Admissible Under Constitutional ...

/ March 2017

Webinar / McDermott Event / March 1, 2017

Redefining Early Stage Investments (RESI) Conference / January 2017

On the Subject / January 31, 2017

San Francisco, California / McDermott Event / January 10, 2017

PharmaRecht, Issue 4 / April 30, 2015

Comparable Drugs in Price Negotiations Under Sec. 130b SGB V

McDermott+Consulting, +Insight / March 2015

CMS Issues Guidance on Policy and Payment Issues Affected by Introduction of ...

On the Subject / January 22, 2015

Pharmind, Issue 11 / November 2014

New Developments On Combating Corruption and Compliance In Healthcare

International Law Office Newsletter, Germany / October 29, 2014

German Perspective on New EU Clinical Trials Regulation

International Law Office Newsletter, Germany / June 18, 2014

Pricing for New Innovative Drugs – Public Payers Attempt New Approach

/ Summer 2014

Special Report / May 12, 2014

Law360 / April 1, 2014

How Changes To 'Dear Doctor Letters' Will Impact Industry

International Law Office Newsletter, Germany / February 26, 2014

Generic Drug and API Producers Deal with the Bolar Exemption

International Law Office Newsletter, Germany / February 19, 2014

Yet another Health Reform and Seizure of Retiring Doctors' Practices

Healthcare Marketing - Das Fachmagazin für Gesundheitsmarken, Issue 1-2 / January 2014

Patent Expirations: Generic Drugs and Active Ingredient Producers from the Perspective of ...

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

... 37